RxDoctor Payments DataLook up a doctor →

Nagendra Myneni, MD

Gastroenterology · Clive, IANPI 1649238643

Payments from drug & device makers

$66,397in general payments, 2019–2025

Across 562 payments — averaging $118.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$35K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$13K
  • AbbVie$12K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$908
  • Regeneron Healthcare Solutions, Inc.$500
  • plus $3K from 29 others

What the payments were for

  • Speaking & faculty fees$51,76578%
  • Travel & lodging$2,5114%
  • Food & beverage$12,02118%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,397 in reported general payments places this provider in the 90th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$109,953
Medicare patients
326
Services billed
2,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide35$26,162
Mesalamine16$11,434
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates120$7,857
Budesonide DrBudesonide22$2,618
Mesalamine ErMesalamine12$2,485
Pantoprazole Sodium156$1,956
Mesalamine DrMesalamine12$1,899
Omeprazole147$1,773
Azathioprine16$1,381
Lansoprazole30$1,192
Esomeprazole Magnesium13$785
Sucralfate16$656
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg26$541
Dicyclomine Hcl28$496
Famotidine19$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$12,250$26,16235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Clive

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →